SALT LAKE CITY, Oct. 23, 2008 (GLOBE NEWSWIRE) -- BSD Medical Corporation (Nasdaq:BSDM) today announced that the European Journal of Cancer has pre-published in its online edition an article titled "Hyperthermia adds to chemotherapy" (EJC 6850) authored by Rolf D. Issels, MD, PhD, of the University Hospital Medical Center Grosshadern and Helmholtz Zentrum Munchen-German Research Center for Environmental Health, Munich Germany. The article highlights the success from clinical studies of deep regional hyperthermia using the BSD-2000 to treat cancer patients.
The European Journal of Cancer is an international comprehensive oncology journal that publishes original research and review articles on clinical oncology (medical, pediatric, radiation and surgical), and on cancer epidemiology and prevention. Central to Dr. Issels article in this prestigious journal is the statement regarding the clinical studies that have been conducted on deep hyperthermia: "At present, we are witnessing the coming of age for regional 'deep' hyperthermia . supported by a wealth of new biological data, the results of clinical trials strengthen the current evidence that hyperthermia combined with chemotherapy is an effective and useful modality which should be integrated in the present cancer treatment armamentarium."
Some of the points addressed by Dr. Issels in the article include:
* Heat multiplies the cytotoxicity of many chemotherapeutic agents.
Recent in-vivo studies have demonstrated a thermal enhancement
ratio (TER) of up to 3-fold maximized at temperatures between
40.5 and 43.0 degrees C.
* The treatment strategy of combining chemotherapy with
hyperthermia may not only be advantageous to the treatment of
cancers, but also may result in a lower risk of treatment-induced
secondary cancers by immunogenic effects.
* For those drugs which show temperature-dependent enhancement, the
rationale for their combined application is that hyperthermia
'targets' the action of the chemotherapeutic agent within the
tumor region. The use of hyperthermia to increase localized
uptake of drugs in the tumor tissue and to minimize side-effects
in healthy tissue is the basic rationale for the upcoming
European HEAT phase III multicentric randomized clinical trial on
pancreatic cancer spearheaded by Dr. Issels.
* The recently concluded randomized multicenter phase III clinical
trial on high risk soft tissue sarcomas (EORTC 62961) has shown
that hyperthermia can target the action of chemotherapy within
the heated tumor region without affecting systemic toxicity.
* Partial-body hyperthermia (PBH) has the potential to provide
simultaneous heating and monitoring of the physiology of the
tumor, which could lead to future broader applications for
hyperthermia.
* PBH is based upon three dimensional multi-antenna applicators
using the BSD-2000 Sigma-Eye applicator integrated in a magnetic
resonance tomograph.
About BSD Medical Corporation
BSD Medical Corp. is the leading developer of systems used to deliver precision-focused microwave/RF energy to diseased sites in the body, including cancer. Its treatments are used to kill cancer directly and increase the effectiveness of companion radiation treatments for certain tumors. For further information visit BSD Medical's website at www.BSDMedical.com.
Statements contained in this press release that are not historical facts are forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. All forward-looking statements are subject to risks and uncertainties detailed in the Company's filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date on which such statements are made, and the Company undertakes no obligation to update such statements to reflect events or circumstances arising after such date.